AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32403118 — intervention group
Group type: EXPERIMENTAL
Intervention: POMA 80 mg/d
Number of subjects: 158
Study 32403118 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-134 20 mg/d
Number of subjects: 158
Study 32403118 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-134 60 mg/d
Number of subjects: 158
Study 32403118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 35195704 — intervention group
Group type: EXPERIMENTAL
Intervention: Food labels & real-time feedback
Number of subjects: 756
Study 35195704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering products by nutritional quality score
Number of subjects: 756
Study 35195704 — intervention group
Group type: COMPARATOR
Intervention: Tax
Number of subjects: 756
Study 35195704 — intervention group
Group type: COMPARATOR
Intervention: Healthier substitute offers
Number of subjects: 756
Study 34307079 — intervention group
Group type: EXPERIMENTAL
Intervention: PROB 3 (3 ml of probiotic)
Number of subjects: 50
Study 34307079 — intervention group
Group type: EXPERIMENTAL
Intervention: AGP (300 ppm zinc bacitracin)
Number of subjects: 50
Study 34307079 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (without probiotic)
Number of subjects: 50
Study 34307079 — intervention group
Group type: EXPERIMENTAL
Intervention: PROB 2 (2 ml of probiotic)
Number of subjects: 50
Study 32217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 40 or 60 mg
Number of subjects: 173
Study 32217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 60 mg (for uncontrolled patients)
Number of subjects: 173
Study 32217809 — intervention group
Group type: COMPARATOR
Intervention: Active control (octreotide/lanreotide)
Number of subjects: 173
Study 32217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (core + extension)
Number of subjects: 173
Study 32217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover group (from active control to pasireotide)
Number of subjects: 173
Study 33882710 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up intervention (ABC)
Number of subjects: 122
Study 33882710 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 122
Study 32185729 — intervention group
Group type: EXPERIMENTAL
Intervention: VisuEvo® (self-administered three times daily for the whole study duration)
Number of subjects: 45
Study 32185729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tear substitute administration)
Number of subjects: 45
Study 33581821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks
Number of subjects: 710
Study 33581821 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 710
Study 33091202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% liposomal TA twice daily
Number of subjects: 60
Study 33091202 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling with 5% TA solution weekly
Number of subjects: 60
Study 33091202 — intervention group
Group type: COMPARATOR
Intervention: 2% hydroquinone every night
Number of subjects: 60
Study 36000999 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP)
Number of subjects: 40
Study 36000999 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing
Number of subjects: 40
Study 34678908 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) + azithromycin + 100 mL 5% glucose injection
Number of subjects: 0
Study 34678908 — intervention group
Group type: COMPARATOR
Intervention: azithromycin + 150 mL 5% glucose injection
Number of subjects: 0
Study 32747522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 1121
Study 32747522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (225 mg at baseline, weeks 4 and 8)
Number of subjects: 1121
Study 32747522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly or monthly
Number of subjects: 1121
Study 32747522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1121
Study 36150707 — intervention group
Group type: COMPARATOR
Intervention: High-effort group (HI)
Number of subjects: 68
Study 36150707 — intervention group
Group type: COMPARATOR
Intervention: Low-effort group (LO)
Number of subjects: 68
Study 33530930 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH approach to advance care planning (ACP)
Number of subjects: 314
Study 32825830 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support at one month after childbirth
Number of subjects: 405
Study 32825830 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social interactions one month after childbirth
Number of subjects: 405
Study 35865278 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising Our Spirits Together (ROST), a technology‐assisted cognitive behavioral therapy (T‐CBT) for depression, delivered virtually in a small group format across 8 weekly sessions via videoconferencing software.
Number of subjects: 84
Study 35865278 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control condition
Number of subjects: 84
Study 33640932 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I seed localization
Number of subjects: 659
Study 33640932 — intervention group
Group type: COMPARATOR
Intervention: Hookwire localization (HWL)
Number of subjects: 659
Study 35276897 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of Medium-Chain Triglycerides (MCTs) daily for 2 weeks
Number of subjects: 0
Study 35276897 — intervention group
Group type: COMPARATOR
Intervention: Long-Chain Triglycerides (Control)
Number of subjects: 0
Study 33373464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg 3 times daily for 3 days, then placebo for 4 days)
Number of subjects: 96
Study 33373464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 times daily for 7 days)
Number of subjects: 96
Study 33373464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 96
Study 32831133 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct therapeutic plasma exchange (TPE)
Number of subjects: 80
Study 32831133 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study 35055542 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Problem-Based Learning (PBL) intervention
Number of subjects: 100
Study 35055542 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 100
Study 35055542 — intervention group
Group type: COMPARATOR
Intervention: Both intervention and waitlist control groups
Number of subjects: 100
Study 35055542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 35005191 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (assessment of drinking behavior, personalized normative feedback, psychoeducation, short quiz)
Number of subjects: 546
Study 32567124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PALO 0.50 mg
Number of subjects: 320
Study 32567124 — intervention group
Group type: COMPARATOR
Intervention: IV PALO 0.25 mg
Number of subjects: 320
Study 36109791 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal and throat spray (1.2 mg iota-carrageenan, 0.4 mg kappa-carrageenan, 0.5% sodium chloride) applied daily for 8 weeks
Number of subjects: 0
Study 36109791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5% sodium chloride) applied daily for 8 weeks
Number of subjects: 0
Study 36109791 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal and throat spray
Number of subjects: 0
Study 36109791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5% sodium chloride)
Number of subjects: 0
Study 33069664 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg caffeine
Number of subjects: 18
Study 33069664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33069664 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine dose > 1.3 mg/kg
Number of subjects: 18
Study 33069664 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 18
Study 32905676 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509
Study 32905676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study 35751744 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment (IPT)
Number of subjects: 50
Study 35751744 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial pulpotomy (PP)
Number of subjects: 50
Study 35751744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pulpotomy (CP)
Number of subjects: 50
Study 35751744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of pulpotomy combined
Number of subjects: 50
Study 32487645 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine uptake (IU) during staging
Number of subjects: 45
Study 32487645 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine uptake (IU) during follow-up
Number of subjects: 45
Study 32487645 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in iodine uptake (IU), MTV, and TLG between timepoints
Number of subjects: 45
Study 32213484 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed, computerised speech and language therapy
Number of subjects: 0
Study 32213484 — intervention group
Group type: COMPARATOR
Intervention: Usual care or attention control
Number of subjects: 0
Study 35851035 — intervention group
Group type: EXPERIMENTAL
Intervention: nHF 6 L/min
Number of subjects: 120
Study 35851035 — intervention group
Group type: COMPARATOR
Intervention: nCPAP alone
Number of subjects: 120
Study 33186518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 66
Study 33186518 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 66
Study 33186518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 34969712 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 for 6 cycles (Arm A)
Number of subjects: 376
Study 34969712 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (Arm B)
Number of subjects: 376
Study 35047809 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (open reduction and internal fixation)
Number of subjects: 126
Study 35047809 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (6-week cast immobilization)
Number of subjects: 126
Study 35904496 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer of a bandage
Number of subjects: 965
Study 35904496 — intervention group
Group type: COMPARATOR
Intervention: Rigid immobilisation
Number of subjects: 965
Study 36219303 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring plus self-titration of antihypertensive medication
Number of subjects: 312
Study 36219303 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study 32401557 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions (SPACE)
Number of subjects: 104
Study 32401557 — intervention group
Group type: COMPARATOR
Intervention: individual child-focused cognitive behavioral therapy (CBT)
Number of subjects: 104
Study 36450540 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent balloon coated with a low-dose formulation of paclitaxel (2 μg/mm2)
Number of subjects: 150
Study 36450540 — intervention group
Group type: COMPARATOR
Intervention: SeQuent Please paclitaxel-coated balloon (3 μg/mm2)
Number of subjects: 150
Study 36450540 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent in ISR substudy
Number of subjects: 150
Study 34269267 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE (Transnasal Humidified Rapid Insufflation Ventilatory Exchange)
Number of subjects: 60
Study 34269267 — intervention group
Group type: COMPARATOR
Intervention: Conventional nasal cannula
Number of subjects: 60
Study 32147536 — intervention group
Group type: EXPERIMENTAL
Intervention: hFCSCs
Number of subjects: 0
Study 32147536 — intervention group
Group type: COMPARATOR
Intervention: SOX9 shRNA interference
Number of subjects: 0
Study 32147536 — intervention group
Group type: COMPARATOR
Intervention: SOX9 expression
Number of subjects: 0
Study 34328050 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured CA training
Number of subjects: 39
Study 33709942 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening with integrated feedback
Number of subjects: 300
Study 33709942 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 33685686 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein High Starch (HPHS)
Number of subjects: 16
Study 33685686 — intervention group
Group type: EXPERIMENTAL
Intervention: High Starch (HS)
Number of subjects: 16
Study 33685686 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP)
Number of subjects: 16
Study 33685686 — intervention group
Group type: COMPARATOR
Intervention: Low Protein Low Starch (LPLS)
Number of subjects: 16
Study 33685686 — intervention group
Group type: COMPARATOR
Intervention: Low Protein High Starch (LPHS)
Number of subjects: 16
Study 33685686 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Low Starch (HPLS)
Number of subjects: 16
Study 33685686 — intervention group
Group type: COMPARATOR
Intervention: Low Starch (LS)
Number of subjects: 16
Study 33151986 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lipopolysaccharide (1 ng/kg) combined with 36‐hour fast and bed rest (CAT)
Number of subjects: 6
Study 33151986 — intervention group
Group type: COMPARATOR
Intervention: Overnight fast (CTR)
Number of subjects: 6
Study 37702364 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness training (MT) course for 4 weeks
Number of subjects: 53
Study 37702364 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) received the same MT course after the first group
Number of subjects: 53
Study 35976753 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape application after tooth extraction
Number of subjects: 0
Study 35976753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice pack and intermittent cryotherapy within 24 h of operation)
Number of subjects: 0
Study 35976753 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (control group)
Number of subjects: 0
Study 33162198 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group with identifiable victim message
Number of subjects: 500
Study 33162198 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group with exponential transmission message
Number of subjects: 500
Study 33162198 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard poster message
Number of subjects: 500
Study 36174257 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-function swing suspension training program (MFSST)
Number of subjects: 47
Study 36174257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 47
Study 34118136 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided antegrade covered stent placement with long duodenal extension (EASL)
Number of subjects: 25
Study 34118136 — intervention group
Group type: EXPERIMENTAL
Intervention: EASL
Number of subjects: 25
Study 34118136 — intervention group
Group type: COMPARATOR
Intervention: Conventional EUS-BD
Number of subjects: 25
Study 32325419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25) added to standard-of-care treatment
Number of subjects: 400
Study 32325419 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment alone
Number of subjects: 400
Study 35551065 — intervention group
Group type: EXPERIMENTAL
Intervention: WebParC access plus standard care
Number of subjects: 203
Study 35551065 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 203
Study 33150409 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of body height (d50%)
Number of subjects: 70
Study 33150409 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected distance (dss)
Number of subjects: 70
Study 33909194 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly pharmaceutical care follow-up for 6 months
Number of subjects: 184
Study 32838701 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated neonatal care kit (iNCK) delivered by Lady Health Workers (LHW)
Number of subjects: 5286
Study 32838701 — intervention group
Group type: COMPARATOR
Intervention: Local standard of care (control)
Number of subjects: 5286
Study 33947355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day (maximum 50 mg/day) for 10 days
Number of subjects: 500
Study 33947355 — intervention group
Group type: COMPARATOR
Intervention: Placebo for oral intake once daily for 10 days
Number of subjects: 500
Study 33947355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 500
Study 34044977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume evacuation (HVE)
Number of subjects: 93
Study 34044977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HVE and intraoral suction device
Number of subjects: 93
Study 34044977 — intervention group
Group type: COMPARATOR
Intervention: Intraoral suction device alone
Number of subjects: 93
Study 35322001 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with bevacizumab
Number of subjects: 93
Study 35322001 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab combined with paclitaxel chemotherapy
Number of subjects: 93
Study 35322001 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with bevacizumab (dMMR patients)
Number of subjects: 93
Study 35322001 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with bevacizumab (PMMR patients)
Number of subjects: 93
Study 35322001 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab combined with paclitaxel chemotherapy (dMMR patients)
Number of subjects: 93
Study 35322001 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab combined with paclitaxel chemotherapy (PMMR patients)
Number of subjects: 93
Study 33569738 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC (binimetinib, encorafenib, and cetuximab)
Number of subjects: 0
Study 33569738 — intervention group
Group type: EXPERIMENTAL
Intervention: EC (encorafenib and cetuximab)
Number of subjects: 0
Study 33569738 — intervention group
Group type: COMPARATOR
Intervention: CI/CF (cetuximab with irinotecan or FOLFIRI)
Number of subjects: 0
Study 32488754 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (100 mg daily for 8 weeks)
Number of subjects: 40
Study 32488754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35525238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for quitting smoking and weight gain prevention
Number of subjects: 41
Study 35525238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) plus contingency management (CM)
Number of subjects: 41
Study 34473031 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 100
Study 34473031 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 100
Study 33724168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulatory follicles (upregulated miRNAs)
Number of subjects: 6
Study 33724168 — intervention group
Group type: EXPERIMENTAL
Intervention: Subordinate follicles (downregulated miRNAs)
Number of subjects: 6
Study 33724168 — intervention group
Group type: COMPARATOR
Intervention: Comparison of miRNA expression
Number of subjects: 6
Study 34284567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pulsed methylprednisolone
Number of subjects: 15
Study 33028418 — intervention group
Group type: COMPARATOR
Intervention: MCT with RT
Number of subjects: 80
Study 33028418 — intervention group
Group type: COMPARATOR
Intervention: HIIT with RT
Number of subjects: 80
Study 35218627 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability training combined with fire needle acupuncture
Number of subjects: 75
Study 35218627 — intervention group
Group type: COMPARATOR
Intervention: Core stability training (Control group)
Number of subjects: 75
Study 33170757 — intervention group
Group type: EXPERIMENTAL
Intervention: Story Friends vocabulary intervention program with explicit vocabulary instruction embedded in prerecorded storybooks and integrated review and practice activities.
Number of subjects: 84
Study 33170757 — intervention group
Group type: COMPARATOR
Intervention: Comparison classrooms with prerecorded storybooks including target vocabulary but without explicit instruction, focusing on general language enrichment strategies.
Number of subjects: 84
Study 35460734 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention adjunct to treatment-as-usual (TAU)
Number of subjects: 647
Study 35460734 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 647
Study 32005561 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat selective laser trabeculoplasty (SLT)
Number of subjects: 90
Study 32005561 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial SLT
Number of subjects: 90
Study 32005561 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat SLT
Number of subjects: 90
Study 35565823 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin group (490 mg catechin, 0.14%, containing 59% epi-type catechin, n = 55)
Number of subjects: 109
Study 35565823 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (0 mg catechin, n = 54)
Number of subjects: 109
Study 34837365 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Communication (BCC) activities for mothers including interactive sessions, audio-visual film screening, and virtual hand wash demonstration.
Number of subjects: 3980
Study 34837365 — intervention group
Group type: COMPARATOR
Intervention: Routine care under the National health program provided by ASHA workers (Control group).
Number of subjects: 3980
Study 34350732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar pegfilgrastim
Number of subjects: 0
Study 34350732 — intervention group
Group type: COMPARATOR
Intervention: US-reference pegfilgrastim
Number of subjects: 0
Study 34350732 — intervention group
Group type: COMPARATOR
Intervention: EU-reference pegfilgrastim
Number of subjects: 0